9 results about "Lung injury" patented technology

The present disclosure provides a unique solution for assisting in the ventilation of lungs of subject that is performed by artificial mechanical ventilator. The solution of the present invention improves the efficiency of the ventilation effect by applying desired pressure profile on portions of the upper body part of the subject in synchronization with the mechanical ventilator operation, thereby creating a desired pressure profile or gradient in the lungs airways to ensure that air pumped into the lungs by the mechanical ventilator spreads more homogeneously in the lungs than without the intervention of the system of the present invention. The application of pressure is determined after analyzing data from sensors of the system that are placed on a plurality of portions on the upper body part of the subject and data received from the mechanical ventilator. These sensors sense data indicative of the ventilation profile within the lungs, i.e. pressure profile along different portions of the lung. The system provides extra-thoracic pressure on the rib cage according to pre-defined and adaptive algorithms based on the physiological status, the respiratory mechanics, and the inhomogeneous nature of lung injury. By applying pressure to the hyperventilated areas and reducing the transpulmonary pressure gradient, the system prevents hyperinflation trauma to the open areas and atelecto-trauma to the closed areas. The system is synchronized with the mechanical ventilator and adapt to changes in the patient's respiratory mechanics.

This invention provides a drug related to lung injury and its application, the drug comprising gabapentin and / or pharmaceutically acceptable salts of gabapentin; the drug reduces the levels of MPO and NOX2 in lung tissue; the application is for the preparation of formulations for the prevention or treatment of lung injury using gabapentin and / or pharmaceutically acceptable salts of gabapentin, or for the study of the mechanism of lung injury caused by surgery; the study is related to manufacturing and application in industry; the drug can prevent or treat damage caused by lung interruption and re-inflation during lung surgery, and has good application prospects in industry.

The present invention relates to a medicament for treating lung injury, in particular, the present invention provides the use of a Annexin for the manufacture of a composition or formulation for one or more uses selected from the group consisting of: (i) preventing and / or treating lung injury; (ii) reducing the number of neutrophils.

This application relates to the use of dexmedetomidine in the preparation of a drug for protecting the glycocalyx structure of lung tissue, a formulation thereof, and its application, belonging to the field of lung injury technology. This application provides a formulation for protecting the glycocalyx structure of lung tissue, the formulation containing dexmedetomidine, which can protect the glycocalyx structure of lung tissue, thereby reducing lung injury and can be used to treat lung injury.

The invention discloses a method for evaluating sepsis lung injury by detecting the crosslinking degree of type VI collagen, and relates to the technical field of medical diagnosis and monitoring. The method at least comprises the following steps: S1, firstly, carrying out sample collection and multi-index detection; s2, performing imaging feature extraction, and automatically identifying fine structure changes in the chest CT image by using a deep learning algorithm; and S3, based on the feature extraction in the S2, establishing a corresponding quality control algorithm, a basic damage scoring model, a dynamic progress prediction model and a comprehensive risk assessment model. The accurate, early-stage and dynamic sepsis lung injury assessment method is provided through multi-dimensional biomarker detection, iconography feature extraction and a dynamic algorithm model, the early diagnosis rate of sepsis lung injury can be remarkably improved, the disease progress can be effectively monitored, the treatment effect can be effectively assessed, and the application prospect is wide. The method has remarkable clinical application prospects and economic benefits, and particularly has important value in intensive care and formulation of personalized treatment schemes.

The invention discloses application of alpha1-acid glycoprotein in preparation of a medicine for treating lung injury caused by acute pancreatitis, and belongs to the technical field of biological medicine. An acute pancreatitis lung injury model is constructed through ORM1 gene knockout mice, the mice are divided into a normal group, a model group and a treatment group for research, target organ pathological injury degree detection, immunohistochemical analysis and serum inflammatory factor expression quantity are performed after injection administration, and the curative effect difference of the gene knockout mice and wild type mice is compared, so that the acute pancreatitis lung injury model is established. And the treatment effect of the alpha1-acid glycoprotein on the acute pancreatitis lung injury is verified. The invention provides a key basis for research, development and preparation of drugs for treating acute pancreatitis lung injury, and has important clinical application value.

The invention provides application of Pt and Pd-S in preparation of a medicine for treating lung injury, and belongs to the field of biological pharmacy. The medicine with the treatment effect on the lung injury and the medicine composition of the medicine have the lung tissue targeting function, have the application potential in preparation of the medicine for treating the lung injury and can be used for clinical treatment of the lung injury.

The present application belongs to the technical field of lung injury treatment and relates to the use of soy extract for the prevention or treatment of uranium-induced lung injury. More specifically, this application relates to the use of soy extract for the manufacture of a medicament with one or more of the following uses: a) improvement of pulmonary fibrosis in a uranium-exposed individual; b) increase of uranium excretion capacity in a uranium-exposed individual; and c) prevention or treatment of uranium-induced lung injury. In this application, the protective effect of soy extract (SE) was investigated in a mouse model of uranium-induced lung injury. The results showed that soy extract can improve pulmonary fibrosis in a uranium-exposed individual.Treatment with soy extract (SE) alleviated uranium-induced pulmonary fibrosis, simultaneously reducing the expression of α-SMA, TGF-β1, and Hyp, and improving uranium-induced pathological changes in lung tissue. Compared to the uranium group, the SE+U group showed a significant reduction in lung uranium concentration of 18.8%. Hematoxylin and eosin staining also revealed a significant reduction in the histological infiltration of inflammatory cells. Soy extract thus possesses a certain protective effect against uranium-induced lung damage.

This invention provides a lung-moistening lotion and its application in the preparation of products for preventing lung injury caused by environmental pollutants. The invention uses loquat leaf extract and bamboo culm extract as active ingredients, employing a low-temperature treatment and mild water extraction process, and compounding them in a specific ratio. The synergistic effect of these two ingredients significantly reduces intracellular reactive oxygen species levels, restores antioxidant defense capabilities, inhibits abnormal expression of inflammatory factors, and improves lung function-related indicators. The product of this invention has high safety, is suitable for long-term consumption, and can be used to prepare functional foods, health foods, or respiratory care products. It also shows promising application prospects in the prevention of lung injury related to nanoplastics.